BlueCrest Capital Management’s Idexx Laboratories IDXX Stock Holding History

BlueCrest Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$250K	–	261
2023 Q1	$250K	Buy	+500	New	+$239K	0.01%	233
2019 Q4	–	Sell	-1,041	Closed	-$283K	–	477
2019 Q3	$283K	Buy	+1,041	New	+$290K	0.02%	382
2019 Q1	–	Sell	-2,326	Closed	-$433K	–	1255
2018 Q4	$433K	Sell	2,326 -596	-20%	-$122K	0.02%	401
2018 Q3	$730K	Buy	+2,922	New	+$709K	0.02%	577
2018 Q2	–	Sell	-3,197	Closed	-$612K	–	1648
2018 Q1	$612K	Sell	3,197 -3,778	-54%	-$697K	0.02%	659
2017 Q4	$1.09M	Sell	6,975 -6,312	-48%	-$994K	0.03%	365
2017 Q3	$2.07M	Buy	+13,287	New	+$2.1M	0.08%	252
2016 Q3	–	Sell	-10,095	Closed	-$937K	–	862
2016 Q2	$937K	Sell	10,095 -9,985	-50%	-$857K	0.04%	373
2016 Q1	$1.57M	Buy	+20,080	New	+$1.45M	0.1%	280
2015 Q4	–	Sell	-7,702	Closed	-$572K	–	1072
2015 Q3	$572K	Buy	+7,702	New	+$552K	0.02%	564

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

BlueCrest Capital Management's IDXX Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2023, closing a stake of 500 shares — an estimated $250K sold.

BlueCrest Capital Management first reported a position in IDXX in Q3 2015 and held it in 10 quarters. The position peaked at $2.07M in Q3 2017. 1,068 funds tracked by Wall St. Rank hold IDXX as of Q2 2023.

BlueCrest Capital Management reported no remaining Idexx Laboratories position as of Q2 2023 after selling out during the quarter.
BlueCrest Capital Management sold 500 Idexx Laboratories shares in Q2 2023, an estimated $250K.
BlueCrest Capital Management first reported a position in Idexx Laboratories in Q3 2015 and held it in 10 quarters.
BlueCrest Capital Management's Idexx Laboratories position peaked at $2.07M in Q3 2017.
1,068 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.